Can an antibody aid neuropsychiatric SLE diagnosis?

Investigators compared a candidate biomarker across three diagnostic groups.

By
Kathryn Wighton
August 27, 2026
4 min

MDSpire News

Overview

Cerebrospinal fluid antisuprabasin antibody demonstrates greater diagnostic accuracy for neuropsychiatric systemic lupus erythematosus (NPSLE) compared to traditional markers.

Background

Neuropsychiatric systemic lupus erythematosus (NPSLE) presents a diagnostic challenge due to overlapping symptoms with other conditions. Accurate identification is crucial for appropriate management and treatment. The study evaluates the diagnostic performance of cerebrospinal fluid antisuprabasin antibody in a cohort of SLE patients with neuropsychiatric symptoms.

Data Highlights

Diagnostic Group	Median CSF Antisuprabasin Antibody (ng/mL)
NPSLE	89
CNS Infection	73
Other Causes	48

Key Findings

Cerebrospinal fluid antisuprabasin antibody had an area under the curve (AUC) of 0.830 for identifying NPSLE.
At a cutoff of 76.36 ng/mL, the antibody demonstrated 81% sensitivity and 74% specificity.
Combining CSF antisuprabasin antibody with other markers improved diagnostic AUC to 0.892.
CSF concentrations of antisuprabasin antibody varied significantly among diagnostic groups, unlike serum concentrations.
The study included 148 patients who met the 2019 EULAR/ACR classification criteria for SLE.

Clinical Implications

The findings suggest that cerebrospinal fluid antisuprabasin antibody may serve as a valuable biomarker for diagnosing NPSLE in patients with SLE. Clinicians should consider its use alongside traditional diagnostic methods to enhance accuracy.

Conclusion

Cerebrospinal fluid antisuprabasin antibody shows promise as a diagnostic tool for NPSLE, warranting further multicenter studies to validate its clinical utility.